Freedman Stephen B, Lee Bonita E, Louie Marie, Pang Xiao-Li, Ali Samina, Chuck Andy, Chui Linda, Currie Gillian R, Dickinson James, Drews Steven J, Eltorki Mohamed, Graham Tim, Jiang Xi, Johnson David W, Kellner James, Lavoie Martin, MacDonald Judy, MacDonald Shannon, Svenson Lawrence W, Talbot James, Tarr Phillip, Tellier Raymond, Vanderkooi Otto G
Department of Pediatrics, Sections of Pediatric Emergency Medicine and Gastroenterology, Alberta Children's Hospital, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada.
Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
BMC Pediatr. 2015 Jul 31;15:89. doi: 10.1186/s12887-015-0407-7.
Each year in Canada there are 5 million episodes of acute gastroenteritis (AGE) with up to 70% attributed to an unidentified pathogen. Moreover, 90% of individuals with AGE do not seek care when ill, thus, burden of disease estimates are limited by under-diagnosing and under-reporting. Further, little is known about the pathogens causing AGE as the majority of episodes are attributed to an "unidentified" etiology. Our team has two main objectives: 1) to improve health through enhanced enteric pathogen identification; 2) to develop economic models incorporating pathogen burden and societal preferences to inform enteric vaccine decision making.
METHODS/DESIGN: This project involves multiple stages: 1) Molecular microbiology experts will participate in a modified Delphi process designed to define criteria to aid in interpreting positive molecular enteric pathogen test results. 2) Clinical data and specimens will be collected from children aged 0-18 years, with vomiting and/or diarrhea who seek medical care in emergency departments, primary care clinics and from those who contact a provincial medical advice line but who do not seek care. Samples to be collected will include stool, rectal swabs (N = 2), and an oral swab. Specimens will be tested employing 1) stool culture; 2) in-house multiplex (N = 5) viral polymerase chain reaction (PCR) panel; and 3) multi-target (N = 15) PCR commercially available array. All participants will have follow-up data collected 14 days later to enable calculation of a Modified Vesikari Scale score and a Burden of Disease Index. Specimens will also be collected from asymptomatic children during their well child vaccination visits to a provincial public health clinic. Following the completion of the initial phases, discrete choice experiments will be conducted to enable a better understanding of societal preferences for diagnostic testing and vaccine policy. All of the results obtained will be integrated into economic models.
This study is collecting novel samples (e.g., oral swabs) from previously untested groups of children (e.g., those not seeking medical care) which are then undergoing extensive molecular testing to shed a new perspective on the epidemiology of AGE. The knowledge gained will provide the broadest understanding of the epidemiology of vomiting and diarrhea of children to date.
在加拿大,每年有500万例急性胃肠炎(AGE)发作,其中高达70%归因于不明病原体。此外,90%的AGE患者在患病时不寻求治疗,因此,疾病负担估计因诊断不足和报告不足而受到限制。此外,由于大多数发作归因于“不明”病因,关于导致AGE的病原体知之甚少。我们的团队有两个主要目标:1)通过加强肠道病原体鉴定来改善健康状况;2)开发纳入病原体负担和社会偏好的经济模型,为肠道疫苗决策提供信息。
方法/设计:该项目涉及多个阶段:1)分子微生物学专家将参与一个经过修改的德尔菲过程,旨在确定有助于解释分子肠道病原体检测阳性结果的标准。2)将从0至18岁、有呕吐和/或腹泻症状且在急诊科、基层医疗诊所就诊的儿童,以及那些拨打省级医疗咨询热线但未寻求治疗的儿童中收集临床数据和样本。要收集的样本将包括粪便、直肠拭子(N = 2)和口腔拭子。样本将采用以下方法进行检测:1)粪便培养;2)内部多重(N = 5)病毒聚合酶链反应(PCR)检测板;3)市售多靶点(N = 15)PCR检测阵列。所有参与者将在14天后收集随访数据,以便计算改良的维西卡里量表评分和疾病负担指数。在省级公共卫生诊所对无症状儿童进行健康儿童疫苗接种时也将收集样本。在初始阶段完成后,将进行离散选择实验,以便更好地了解社会对诊断检测和疫苗政策的偏好。获得的所有结果将整合到经济模型中。
本研究正在从以前未接受检测的儿童群体(例如未寻求医疗护理的儿童)中收集新样本(例如口腔拭子),然后对这些样本进行广泛的分子检测,以从新的角度了解AGE的流行病学。所获得的知识将提供迄今为止对儿童呕吐和腹泻流行病学的最广泛理解。